Latham & Watkins and Gowling WLG have taken roles on one of the biggest pharma deals of the year so far, as drug giants AstraZeneca and Daiichi Sankyo collaborate on a $6.9 billion cancer treatment.

The deal will see the global development and commercialisation of Japan-headquartered Daiichi Sankyo’s lead antibody drug, trastuzumab deruxtecan. It is designed to help treat a range of cancers including breast and gastric cancer, as well as non-small cell lung and colorectal cancer.